Cargando…
T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients: A Randomized, Double-Blind Clinical Trial
BACKGROUND: T-cell vaccination (TCV) for multiple sclerosis (MS) refers to treatment with autologous anti-myelin T-cells, attenuated by irradiation. Previously published clinical trials have been all open-labeled. AIM: To evaluate the safety and efficacy of TCV in progressive MS, in a double-blind,...
Autores principales: | Karussis, Dimitrios, Shor, Hagai, Yachnin, Julia, Lanxner, Naama, Amiel, Merav, Baruch, Keren, Keren-Zur, Yael, Haviv, Ofra, Filippi, Massimo, Petrou, Panayiota, Hajag, Shalom, Vourka-Karussis, Urania, Vaknin-Dembinsky, Adi, Khoury, Salim, Abramsky, Oded, Atlan, Henri, Cohen, Irun R., Abulafia-Lapid, Rivka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522721/ https://www.ncbi.nlm.nih.gov/pubmed/23272061 http://dx.doi.org/10.1371/journal.pone.0050478 |
Ejemplares similares
-
Long-Term Clinical and Immunological Effects of Repeated Mesenchymal Stem Cell Injections in Patients With Progressive Forms of Multiple Sclerosis
por: Petrou, Panayiota, et al.
Publicado: (2021) -
NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness
por: Mizrachi, Tehila, et al.
Publicado: (2018) -
Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis
por: Petrou, Panayiota, et al.
Publicado: (2022) -
Inhibition of Effector Function but Not T Cell Activation and Increase in FoxP3 Expression in T Cells Differentiated in the Presence of PP14
por: Ochanuna, Zohar, et al.
Publicado: (2010) -
Cerebrospinal Fluid (CSF) Exchange with Artificial CSF Enriched with Mesenchymal Stem Cell Secretions Ameliorates Experimental Autoimmune Encephalomyelitis
por: Valitsky, Michael, et al.
Publicado: (2019)